|
|
 |
RESEARCH
Community Based
Clinical Trial at Cleveland
Clinic
READ MORE
Q&A: Laurent
Sabbagh, University of Toronto, Recipient of an
LLS Career Development
Program grant
READ MORE
| |
 |
 |
PATIENT
SERVICES
CMO Corner - LLS Chief Medical
Officer Barton Kamen, M.D., Ph.D., Talks about
the Three T's
READ
MORE
Spotlight on Some
Local Education Programs For Leukemia, Lymphoma
and Myeloma
Awareness
Month
READ MORE
LLS Hosts
an Education Program for
Family
Doctors
READ
MORE
Trish Greene Back to School
Program
READ MORE
Upcoming
Teleconferences
READ
MORE
Co-Pay Assistance Program
Broadens Funding
READ
MORE
We'd Like to Hear from
You!
READ
MORE
LLS Clinical Trail Service -
TrialCheck® READ
MORE
| |
FUNDRAISING
UPDATES
A Premier Triathlon
and a Signature Marathon
READ MORE
Kendall Kollection to
Debut Athletic Skirts at Women's Running
Magazine Women's Half Marathon and 5K to Benefit
The Leukemia & Lymphoma Society
READ MORE
Light The Night Walk -
Featuring Some Company and Family and Friends
Teams
READ
MORE
ADVOCACY
Health Care
Policy READ
MORE
FROM THE
LLS BLOG READ MORE
| |
|
|
|
 | | | | | |
|
|
|
 Cleveland
Clinic and The Leukemia & Lymphoma Society
Open Clinical Trial at Community
Center
Cleveland
Clinic's Taussig Cancer Institute, in its
partnership with The Leukemia & Lymphoma
Society (LLS), last month opened its first
regional Phase I/Phase II clinical trial at the
Clinic's Cancer Center in Independence, OH, as
part of an initiative to increase participation
in research studies and give patients easier
access to the newest treatments.
This
trial is the result of an innovative
collaboration between Cleveland Clinic and LLS
to further the advancement of new treatments for
blood cancer patients and to make clinical
trials available to patients in their own
communities.
"This is a win-win for
patients and researchers in the blood cancer
community," said Dr. John Sweetenham, director
of clinical research in the Taussig Cancer
Institute. "Patients can have access to the
latest treatments without having to travel far
from home or transferring their care to a
different physician just to participate, and
these changes will make it easier for
researchers to recruit patients, thus speeding
up the research and approval process for
important new drugs."
The
trial at the Cancer Center will study a
novel treatment for patients with relapsed or
refractory chronic lymphocytic leukemia and
indolent B-cell lymphomas. This trial, along
with all future regional trials, will also be
open on the Clinic's main campus in Cleveland,
to maximize participation and access.
Previously, such trials would only have been
available to patients at the main
campus.
Patients are often reluctant to
participate in clinical trials if it requires
them to leave their doctor or travel outside
their community. Offering clinical trials at
regional centers allows patients who see an
oncologist at that location to remain with their
own doctor.
Cleveland Clinic and LLS
plan to undertake at least six trial in the
coming years. In addition to the Independence
Cancer Center, other clinical trials will be
opened at Hillcrest Hospital, Fairview Hospital
and the Cleveland Clinic Family Health Center in
Beachwood in the future.
Patients,
caregivers and physicians interested in learning
more information on clinical trials at Cleveland
Clinic can call the Cancer
Answer Line at (866)
223-8100.
Back to
the top
 Q&A: Laurent
Sabbagh, Ph.D.
Laurent Sabbagh,
Ph.D., University of Toronto, is a recipient of
an LLS Career Development Program grant.
Studying potential targets of drug therapy for
NHL and CLL patients.
What is the biomedical
problem/issue that you are trying to
resolve?
One of the molecules
(TRAF1) that I am studying is involved in the
survival of cells of the immune system. Elevated
levels of TRAF1 have been observed in ~50% of
Chronic Lymphocytic Leukemia (CLL) and
Non-Hodgkin lymphoma (NHL) cases. However, how
elevated levels of TRAF1 contribute to cancer
formation remains to be determined. One of my
main goals is to elucidate this process by
studying the cellular survival pathways that
require its activity.
What's novel or
innovative about your approach?
Several new technologies are
currently available to perform my studies. I
have integrated several of these in a primary
mammalian cell system that allows me to study
TRAF1 and other molecules at the somewhat
elevated levels found in cancer cells rather
than at the exceptionally high (over-expression)
levels more typically studied in experimental
systems. My approach should facilitate the
identification of molecular targets for drug
discovery, avoiding "fishing" out false-positive
targets that are commonly found in
over-expression studies.
How will your work one
day help patients?
My research has
the potential for aiding the design of novel
therapies that target specific molecules
involved in cellular malignancies. Since the
expression levels of TRAF1 are elevated in CLL
and NHL, understanding the role of elevated
TRAF1 in leukemia and lymphoma will allow the
design of specific drugs that can target the
cellular survival pathways that are dependent on
TRAF1 expression levels and thereby potentially
prevent malignant growth.
Are you close to
clinical trials?
There is a lot of
work that needs to be done before my findings
translate into the clinic. However, the amount
of information that will be generated from my
current research has the potential to identify
multiple targets for drug therapy which can then
be used in clinical trials.
What other projects
are you excited about and believe will benefit
patients?
My research is also focused
on understanding the immune system. More
specifically, I would like to manipulate cells
of the immune system to enhance their anti-tumor
function. I have engineered a "transgenic" mouse
model that will prove invaluable in the
development of novel immunotherapies. The
transgenic mouse will be used to find new
strategies to enhance the anti-tumor function of
immune T cells.
What are some of your
hobbies and non-research interests?
I
enjoy spending time and traveling with my
family. I also have a passion for reading both
novels and history books. For the past year, I
have been coordinating and teaching the basic
immunology course at the Canadian College of
Naturopathic Medicine.
Back to
the top
| | |
|
CMO
Commentary - Barton Kamen, M.D., Ph.D
 ( The CMO Commentary will be an occasional
feature by The Leukemia & Lymphoma Society
(LLS) Chief Medical Officer Barton Kamen, M.D.,
Ph.D. In addition to co-directing LLS's major
biomedical research grants with Chief Science
Officer Louis DeGennaro, Ph.D., Dr. Kamen
manages LLS's medical literature and
professional medical education programs, and
provides medical and scientific guidance to
LLS's patient services and public policy
activities. He has worked for many years in the
field of pediatric hematology
oncology.
The Three T's of
Therapy
When talking about
identifying appropriate therapies for patients I
have started to draw an analogy with our school
basics of the three Rs: "reading, riting, and
rithmetic." I use the three Ts of typing,
tailoring and targeting to explain our path to
better treatment.
Typing is to remind us
that cancer is really a very plural word:
cancers. When I was first initiated into the
field, we only talked about acute lymphocytic
leukemia and acute nonlymphocytic leukemia - not
even acute myelocytic leukemia. Now we have
multiple types of acute lymphocytic leukemia,
eight morphologic subtypes of acute myelocytic
leukemia, and more than 100 subtypes with
molecular biology factored in. Lymphoma has
recently been recognized to have more than 60
subtypes. Unless there is a final common
metabolic pathway, the many dysregulated
pathways leading to a malignancy thwart a one
size fits all for cancers.
Tailoring is
to remind us that patients are a very
heterogeneous group. If only treating a
genetically identical tumor in genetically
inbred mice was our problem! But in truth, there
is great diversity in the patients we see, and
they metabolize drugs differently and have
varying response rates to treatments and their
toxicities. Our new understanding of genetics
will likely allow different and more relevant
classification of patients.
Targeting is
the elusive magic bullet. It works when we
can identify an inhibitor that "turns off" the
malignant process. The poster child for such a
molecule is imatinib (Gleevec) in controlling
chronic myelocytic leukemia. Although it does
not cure the disease, it certainly increases
patient life span and quality by very large
amounts. But this is a highly unusual case. In
most cases, there are a multitude of
derangements in the regulatory pathways leading
to abnormal cell growth. The bullseye of cancer
treatment is a moving target.
Yes we
have made great strides but the cautionary
reminder is how much more difficult it will be
to move ahead without new agents and more
complete knowledge of the patient and the
disease. As Sir William Harvey noted, "What we
know is infinitely less than all that remains
unknown."
For more information about
treatment options click
here.
Back to the top
Spotlight on Some Local
Education Programs for Leukemia, Lymphoma
and Myeloma
Awareness Month
September,
being Leukemia Lymphoma and Myeloma Awareness
Month, is a time to shed light on the needs of
people touched by blood cancers and the ways
they can be helped. It is also a good time to
put a spotlight on some of the ways that The
Leukemia & Lymphoma Society (LLS) helps
patients and their families.
Through its
64 chapters in the United States and Canada, LLS
offers a comprehensive array of education and
support services to blood cancer patients and
their families. There are family support groups,
patient education workshops featuring health
experts, and First Connection - a peer-to-peer
support program that matches newly diagnosed
patients with trained volunteer survivors. A
back to school program helps children treated
for cancer transition back to school. LLS also
provides financial assistance to patients with
significant financial need and an insurance
co-pay assistance program.
Throughout September, chapters across
the country have been conducting a variety of
critical education programs for patients,
caregivers and family members. LLS also offers
programs specifically designed for healthcare
professionals as this directly benefits patients
and their families by expanding the knowledge
and expertise of those who are on the frontlines
of treating patients.
Some highlights of
the month include:
Virginia Chapter:
Five programs during the month, including
a Blood Cancer Conference attended by more than
200 patients, caregivers, parents, nurses and
social workers. A program on stem cell
transplants; an education program about
understanding blood cell counts; and a program
called Men and Caner, geared specifically to
African American men. And finally, a program for
patients and caregivers called "How Physicians
Decide Treatment Protocols."
Northern New Jersey
Chapter: A program for more than
200 hematologists and oncologists called
"Upcoming Trends in the Treatment of
Hematological Malignancies." The program
included a panel of speakers and an opportunity
for attendees to engage in educational
discussions with the speakers.
Kansas Chapter:
The longest running symposium of LLS, the
"38th Annual Dr. William Dameshek Symposium for
Leukemia & Related Cancers" was held on
Sept. 26, 2009. Attended by an audience of
more than 100 hematologists and oncologists from
around the state, as well as internal medicine
and other primary care residents, medical
students and oncology nurses, this medical
symposium updated participants on recent
advances in research and treatment of patients
with blood cancers.
LLS's web site - www.LLS.org
is the definitive resource for information
about blood cancers and its Information Resource
Center (IRC) is a call center staffed by
master's level social workers, nurses and health
educators who provide information, support and
resources to patients and their families and
caregivers. IRC information specialists are
available at (800) 955-4572, Monday through
Friday, 9 a.m. to 6 p.m. ET. To connect with
your local chapter visit www.lls.org and enter
your zip code in the chapter finder.
Back to the
top
Helping
Family Doctors to Make an Early
Diagnosis
Recognizing that
family practitioners are on the frontlines of
identifying serious illnesses such as cancer,
The Leukemia & Lymphoma Society (LLS) has
been conducting a series of programs to help
family practice doctors learn to identify the
earliest signs of a potential blood
cancer.
The series continues on October
14 when LLS hosts a symposium during the 2009
American Academy of Family Physicians Scientific
Assembly in Boston. The program, entititled
"Blood Cancer: Early Diagnosis, Treatment
& Survivorship; Cancer Case Studies for the
Primary Care Physician," will feature Barton
Kamen, M.D., Ph.D, chief medical officer of LLS,
and Kevin C. Oeffinger, M.D., of Memorial
Sloan-Kettering Cancer Center.
The goal of the program will be
to help family doctors recognize the distinct
signs and symptoms associated with blood cancers
and how to select appropriate diagnostic tools,
so they have a better chance of making an early diagnosis. Drs. Kamen and
Oeffinger will emphasize the importance of
follow-up care for cancer survivors, and will
discuss how to identify the late effects
associated with treatments, as well as follow-up
tests used to screen for the recurrence of
cancer to improve long-term
survival.
"The earlier that a blood cancer
is detected the better the chance for a good
outcome," says Dr. Kamen. "Since the family
physician is usually the first health
professional a patient will see, the information
that doctors can learn at this symposium could
be critical and help save lives."
Adds Dr. Oeffinger, "Survivors
of pediatric and young adult cancer face
substantial health risks as they get older.
Since most survivors are followed by their
primary care physician it is important for these
doctors to understand their patients' unique
risks and the screening strategies that can save
lives."
For more information click
here.
Back to the
top
Featured Education
Program
The Trish Greene Back to School
Program for Children with Cancer was designed to
increase communication among health care
professionals, parents, patients and school
personnel to assure youngsters a smooth
transition from active treatment back to school.
Back to the
top
Archived
Teleconference
Advocating
For Your Child's Learning Needs: Through
Treatment
and Beyond
This
program featured Daniel Armstrong, PhD,
professor & associate chair, Department of
Pediatrics, director, Mailman Center for Child
Development, associate chief of staff, Holtz
Children's Hospital at the University of Miami,
Jackson Memorial Medical Center, director,
University of Miami Sickle Cell Center, Miami,
Florida.
This program is part of our
Focus on
Childhood Cancers Educational Series and
was sponsored by The Leukemia and Lymphoma
Society.
Upcoming
Teleconferences
Wednesday, October 14,
2009 - 12:00 - 1 p.m. ET
Treating Uncommon Lymphomas:
Dialogue With an Expert on T-Cell, MALT, and
Waldenström Macroglobulinemia
This program will feature
Richard R. Furman, M.D., Assistant
Professor, Center for Lymphoma and
Myeloma, Division of Hematology and Oncology,
Weill Medical College of Cornell University, New
York, NY. Participants will
have the opportunity to ask the presenter
questions during the program. This program is sponsored by The Leukemia
& Lymphoma Society and is supported by
grants from
Allos Therapeutics,
Inc. and Eisai Inc.
Thursday, October 29,
2009 - 12:00 - 1:30 p.m.
ET
Managing
Myeloma: An Expert's Update
This program will feature
Kenneth C. Anderson, M.D., Kraft Family
Professor of Medicine, Harvard Medical School,
Chief, Division of Hematologic Neoplasia,
Director, Lebow Institute for Myeloma
Therapeutics and Jerome Lipper Multiple Myeloma
Center, Dana-Farber Cancer Institute, Boston,
MA. Participants will have the opportunity to
ask the presenter questions during the program.
This program is supported by
grants from Celgene
Corporation and Millennium
Pharmaceuticals, Inc
NEW
OPTION
You now have the option of
listening to the program from your computer
(webcast). When you register for the program,
you will be asked if you want to participate by
phone or via webcast. If you choose webcast, you
will be sent an e-mail providing you with a URL
link for you to click on the day of the
program.
To learn more about these
programs click here.
Back to
the top
 Co-Pay
Assistance Program Broadens
Funding
Qualified
patients with chronic myelogenous leukemia and
myeloma can now receive up to $5,000 in
assistance from The Leukemia & Lymphoma
Society's (LLS) Co-Pay Assistance Program. The
aid helps offset prescription drug co-pays and
other insurance-related expenses according to
disease diagnosis. For more information, visit
www.LLS.org/copay or call (877) 557-2672.
The LLS Co-Pay Assistance program is pleased
to announce a new tool to help patients and
providers submit online applications quickly and
easily. The Co-Pay Assistance program provides
financial assistance for health insurance
payments and blood cancer treatment co-pay
obligations to qualified patients. For more
information, visit www.LLS.org/copay or call (877) 557-2672.
Back to
the top
We'd Like to Hear from
You!
Please give
us your feedback after you read an LLS
Publication by completing our
evaluation:
LLS Disease &
Treatment Publications - Survey for Patients,
Family and Friends
Nos gustaría saber sus
opiniones!
Por favor denos sus
comentarios después de leer una publicación de
LLS completando nuestra evaluación:
Publicaciones de LLS sobre
enfermedades y tratamiento: Encuesta para
pacientes, familiares y
amigos
Back to the
top
The Leukemia & Lymphoma
Society Clinical Trial Service
-TrialCheck® 
Easily find
clinical trials near you through the
LLS-supported TrialCheck® website, a
clinical trial search
service that offers patients and caregivers
immediate access to listings of all leukemia,
lymphoma and myeloma and related blood cancer
clinical trials. Answer just a few simple
questions and a list of available clinical
trials related to your cancer will appear in an
easy to read list of search results.
Back to the
top
| | |
|
A Premier Triathlon and a
Signature Marathon
Team In Training (TNT) participants
recently completed one of the country's premier
triathlons, The Nation's Triathlon to Benefit
The Leukemia & Lymphoma Society (LLS), and
are gearing up to participate in another
signature event, The Nike Women's Marathon to
benefit The Leukemia & Lymphoma Society.
The Nation's Triathlon took place on
September 13, and more than 4,400 triathletes,
including 585 participants from TNT, took part.
The TNT participants raised $2.4 million to help
LLS find cures for blood cancers and serve
thousands of patients and their families.
One outstanding participant was
Kaitlin Sighinolfi, 27, of Washington, D.C.
Kaitin was diagnosed with non-Hodgkin lymphoma
in 2007, when an apple sized tumor was
discovered between her lungs. An aggressive
regimen of chemotherapy combined with the
targeted antibody drug, Rituxan, brought the
cancer into remission. Kaitlin says she
took on the triathlon to prove to herself and
others that she can overcome physical
challenges.
Meanwhile, approximately
4,000 TNT participants are preparing to descend
on San Francisco for the 6th Annual
Nike Women's Marathon on October 18, 2009. They
are expected to raise $14 million for blood
cancer research and patient services.
One of these will be Marcella
Marcheschi, of San Francisco, who was 26 when
she heard the words that would forever change
her life. "I don't think words can explain what
it feels like to be told you have cancer," says
Marcheschi of learning of her diagnosis of
Hodgkin lymphoma in January of 2008. "All of a
sudden I wasn't a young healthy 20-something any
more. I had something in my body killing
me."
A grueling regimen of chemotherapy,
radiation and steroids was a test of endurance,
but finally knocked out the cancer. She will run
the race alongside her sister, Gabriella, 30,
also of San Francisco, and their mother, Maria
Marcheschi, of San Mateo, Ca. They will be
running the half marathon. Marcheschi says she
and her family feel an overwhelming desire to
give back.
"We're all so thankful for
LLS and all the amazing things that have been
accomplished through TNT. There's no doubt in my
mind that I'm here today because of LLS and I
will forever be grateful to the people who make
the organization what it is. Cancer is scary and
devastating, but TNT has proven that together we
have the power to not just save more lives but
ultimately we have power to potentially change
the prognosis of cancer forever."
visit
www.teamintraining.org to learn more.
Back to the
top
Kendall Kollection Skirts to
debut at Women's Running Magazine Women's Half
Marathon & 5k in St.
Petersburg
Renowned designer, Jackie McFee, who
created a fashionable collection of school
supplies called the Kendall Kollection, to
benefit The Leukemia & Lymphoma Society
(LLS), has now designed athletic skirts for the
same colorful Kendall Kollection. The skirts
will make their debut at the expo of the Women's
Running Magazine Women's Half Marathon and 5K to
Benefit The Leukemia & Lymphoma Society the
weekend of November 21-22, in St. Petersburg,
Fla.
 McFee (www.jackiemcfee.com), has partnered with SkirtSports ( www.skirtsports.com), the leader of the fitness skirt
category, to produce the five-piece Kendall
Kollection Athletic Apparel line. A portion of
the Kendall Kollection sales will benefit
LLS.
The Kendall
Kollection print is inspired by Jackie's young
cousin, Kendall Sierens, who was diagnosed with
leukemia when she was just two-years-old.
Moved to take action, Jackie designed a bright
floral print for a range of school supplies in
an effort to raise awareness and funds for LLS.
Now the Kendall Kollection print is expanding
its reach while continuing to support LLS
through this partnership with SkirtSports. Now
six years old, Kendall is in
remission.
"This collection is an amazing
opportunity to attract a more diverse audience
with the Kendall Kollection apparel line," says
McFee. "It's the perfect combination of a
beautiful product and a meaningful
cause."
Five styles will be produced by
SkirtSports featuring the Kendall Kollection
print: the Kendall Splice Tank, Kendall
RunnersDream long sleeve, Kendall Mini Hoodie,
Kendall GymGirl Skirt and Kendall Summer Breeze
Skirt. The Kendall Kollection Athletic Apparel
will also be available to purchase at
SkirtSports retail locations and on www.skirtsports.com after the event.
Back to the
top
 Company Teams and Friends and Family
Teams key to Success
The Light The
Night® Walk season is heating up,
with great participation anticipated across the
country. Teams made up of both friends and
families, as well as both national and local
companies, are a big part of the campaign's
success each year.
"Light The Night
provides businesses a great opportunity to
motivate their employees to do something great
for their communities," said LTN National
Director of Partnership Development Kaye
Skonieczny. "Walk teams show how much these
companies care."
For example, Stater
Bros. Markets, the largest privately owned
supermarket chain in Southern California, had a
team of nearly 900 walkers at the Angel Stadium
walk in Orange County, Ca., on August 22. In
addition, the stores sold paper Light The Night
Walk balloons. Customers make a donation to LLS
and write their name on the paper balloon, which
is displayed in the store. Between the walk team
and the paper balloon sales, Stater Bros. raised
more than $300,000 to support blood cancer
research and patient services. In addition,
Stater Bros. delivered and provided water for
all the walkers at Angel Stadium.
Bill
Taylor is the team captain for the Denver office
of the national Cisco Systems Walk Team. The
Denver team walks in honor of Taylor's, son,
Ryan, 13, a leukemia survivor. In 2007, Taylor
and his wife, Karen, hosted a golf tournament as
a fundraiser to complement the funds raised at
the walk, and the event raised $15,000. Last
year the tournament grew to include more
golfers, as well as a silent and live auction,
raising $60,000, and they are on track to raise
the same amount for this year's event. The
Denver walk takes place at Washington Park on
October 1.
"After
Ryan was diagnosed our family participated in
the Light The Night Walk in Denver for the 2006
walk," says Karen Taylor. "We were so amazed by
the support and all the wonderful things that
LLS does for people and families impacted by
leukemia. So much so, that we felt we had
to be more involved in its mission to cure blood
cancers and improve the quality of life of
patients and their families. It is an honor to
be associated with LLS."
Friends and family teams are also having
a great impact. In Los Angeles a team called
Blood, Sweat & Tears, led by a group of
teenagers, has consistently raised around
$30,000 a year. Walking since 2006 in honor of
big sister and friend, Shayna Bordy, a lymphoma
survivor, Jenna Bordy leads the team this year
with little sister, Samantha. Applying for
foundation money and local grants is one of the
keys to the team's annual
success.
Light
The Night Walk events take place every fall in
communities throughout the United States and
Canada. Walkers raise funds to help LLS cure
leukemia, lymphoma and myeloma, and provide
services to patients and their families. The
lighted balloons they carry are a sight to
behold. There's still time to sign up for Walks
in many communities. Please visit
www.lightthenight.org to learn about the walk
and ways you can become
involved.
Back to the
top
| | |
 The
Leukemia & Lymphoma Society Statement on
Health Care
Reform
The nation is
now in the midst of a historic debate on the
future of our health care system that has
generated considerable discussion across the
airwaves, newspapers, Internet and around
kitchen tables. The focus of this attention has
been the pending congressional proposals to
change the way Americans access medical care
that will most certainly impact how current and
future blood cancer patients receive their
treatment.
The Leukemia &
Lymphoma Society (LLS) is intimately familiar
with the challenges currently faced by patients
and is dedicated to ensuring that they have
access to high quality health care. This
includes patient access to clinical trials,
access to promising new therapies, and
guaranteed access to affordable health insurance
coverage.
Any health care reforms,
however, should also preserve and enhance the
strengths of the current system.
America must retain its leadership in
cutting-edge medical research and promote
innovation that has created new targeted
therapies, such as Gleevec, which has
dramatically improved survival rates for chronic
myelogenous leukemia. Health care reform also
must ensure that treatment decisions are made by
a patient and their doctor.
The
debate on health care reform is ongoing and
consensus has not yet been formed. Consequently,
LLS is not endorsing any pending legislative
proposal. Consistent with its mission and
Strategic Plan, LLS has, however, adopted a set
of principles on health care reform that will
guide evaluation of debate. They
include:
- Research: Reforms
should preserve and accelerate the acquisition
and application of scientific understanding to
advance the prevention, diagnosis and treatment
of leukemia, lymphoma and myeloma.
- Clinical
Trials: LLS has worked steadily to
enhance and support patient accrual in clinical
trials. Clinical trials coverage requirements
and other consumer protections already enacted
should remain in effect.
- Access:
Health care reforms should provide all
blood cancer patients access to high quality
treatments. A goal of reform should be enhanced
availability and support for underserved
patients.
- Navigation:
Ensure that blood cancer patients have access to
information, care and services. Coordination of
cancer care has been fragmented and reforms
should provide patients with comprehensive
support through the continuum of the cancer
journey.
- Patient
Involvement: Cancer patient
advocates and health care professionals
providing cancer care should be included in any
advisory panel charged with defining the
benefits package. An advisory panel should also
have procedures for public participation and
permit rapid revision of the benefits package,
as medical evidence progresses.
For more information, please
contact George Dahlman, senior vice president,
public policy, or Mark Pascu, national director,
federal affairs, Office of Public Policy, at
(703) 535-6650 or via email at george.dahlman@lls.org or mark.pascu@lls.org.
Back to the
top
| | |
| | | |
|
|
 |
|
You are currently receiving
national news from LLS. Your
local chapter may also produce a local
eNewsletter called The Chapter
Report. If you'd like to receive
The Chapter Report please contact your
local chapter to subscribe.
Click here to
find your chapter's contact information.
|
Supported by an
unrestricted educational grant from   |
|
|
eNEWSLINE is
published by The Leukemia & Lymphoma
Society®
Home Office | 1311 Mamaroneck Avenue
| White Plains, NY
10605
914.949.5213 | www.LLS.org
© 2009 The Leukemia
& Lymphoma Society
All Rights
Reserved
|
|
|
| Participating member of An Alliance of
America's Premier Health Charities in the
Combined Federal Campaign, the National
Coalition for Cancer Research and Blood Cancer
Coalition. This publication is designed to
provide information in regard to the subject
matter covered, and is distributed as a public
service by The Leukemia & Lymphoma Society,
with the understanding that LLS is not engaged
in rendering medical or other professional
services.
The Leukemia &
Lymphoma Society® (LLS) is
the world's largest voluntary health agency
dedicated to blood cancer. The LLS mission: Cure
leukemia, lymphoma, Hodgkin's disease and
myeloma, and improve the quality of life of
patients and their families. LLS funds
lifesaving blood cancer research around the
world and provides free information and support
services.
Founded in 1949 and
headquartered in White Plains, NY, LLS has
chapters throughout the United States and
Canada. To learn more, visit www.LLS.org or
contact the Information Resource Center at (800)
955-4572, Monday through Friday, 9 a.m. to 6
p.m. ET. www.lls.org. |
|
|
Visit our
e-Store
& Special Offers page,
where you can support businesses that support
LLS.
Please remember LLS in your will
or as a beneficiary in your retirement plan. For
information, call (888)
773-9958.
| | | | | |
|
| | | | |
